Table 4.
Survival distributions associated with autoantibody levels stratified by stage and initial treatment. Log-rank test comparison of survival distributions by grouped level (4th quartile [Q4]) and, hazard ratios (HR) and 95% confidence intervals (CI) from age- and sex-adjusted Cox-proportional hazards models
| Clinical Factor | Autoantibody | <Q4 N Cases (days) | Q4 N Cases (days) | p-value* | HR | 95% CI | HR | 95%CI** |
|---|---|---|---|---|---|---|---|---|
| N (med. survival) | N (med. survival) | |||||||
| CTDSP1 | 216 (313) | 80 (345) | 0.05 | 0.77 | 0.59-1.01 | 0.85 | 0.60-1.2 | |
| MAPK9 | 207 (305) | 89 (388) | 0.16 | 0.90 | 0.69-1.2 | 0.84 | 0.46-1.5 | |
| NR2E3 | 194 (301) | 102 (387.5) | 0.07 | 0.86 | 0.66-1.1 | 0.91 | 0.66-1.3 | |
| Stage | ||||||||
| CTDSP1 | ||||||||
| local | 22 (420.5) | 11 (533) | 0.28 | 0.76 | 0.31-1.9 | 0.95 | 0.23– 3.9 | |
| regional | 103 (391) | 36 (417) | 0.23 | 0.72 | 0.52-1.1 | 0.88 | 0.54– 1.4 | |
| distant | 18 (297.5) | 8 (334.5) | 0.28 | 0.81 | 0.51-1.3 | 0.82 | 0.44– 1.5 | |
| unknown | 73 (221) | 25 (314) | 0.89 | 1.3 | 0.50-3.1 | 1.7 | 0.48– 6.1 | |
| MAPK9 | ||||||||
| local | 22 (343.5) | 11 (515) | 0.27 | 0.81 | 0.33-2.0 | 0.57 | 0.07–4.9 | |
| regional | 95 (343) | 44 (430) | 0.42 | 0.87 | 0.60-1.3 | 0.72 | 0.31–1.7 | |
| distant | 68 (330.5) | 30 (225.5) | 0.54 | 2.4 | 0.70-8.0 | 1.4 | 0.44–5.1 | |
| unknown | 22 (224.5) | 4 (238) | 0.35 | 0.98 | 0.63-1.5 | 11 | 1.06- 113 | |
| NR2E3 | ||||||||
| local | 21 (388) | 12 (538.5) | 0.10 | 0.65 | 0.25-1.7 | 0.77 | 0.23–2.6 | |
| regional | 87 (336) | 52 (443.5) | 0.35 | 0.85 | 0.60-1.2 | 0.85 | 0.55–1.3 | |
| distant | 6 (370.5) | 32 (242) | 0.80 | 1.2 | 0.74-1.8 | 1.5 | 0.77–8.2 | |
| unknown | 20 (226.5) | 6 (256.5) | 0.95 | 1.1 | 0.38-3.5 | 2.4 | 0.73–8.2 | |
| Initial Treatment | ||||||||
| CTDSP1 | ||||||||
| None/palliative | 79 (255) | 29 (272) | 0.96 | 1.1 | 0.68–1.6 | 1.1 | 0.58–2.1 | |
| Chemo/radiation | 68 (291) | 24 (350.5) | 0.04 | 0.64 | 0.39–1.06 | 0.75 | 0.40–1.4 | |
| Surgical resection | 69 (515) | 27 (562) | 0.11 | 0.63 | 0.38–1.04 | 0.70 | 0.39–1.3 | |
| MAPK9 | ||||||||
| None/palliative | 77 (262) | 31 (255) | 0.85 | 1.05 | 0.69–1.6 | 1.8 | 0.65–4.7 | |
| Chemo/radiation | 70 (282) | 22 (361) | 0.21 | 0.84 | 0.50–1.4 | 0.76 | 0.25–2.3 | |
| Surgical resection | 60 (549) | 36 (538.5) | 0.78 | 0.95 | 0.60–1.5 | 0.64 | 0.21–1.9 | |
| NR2E3 | ||||||||
| None/palliative | 72 (256.5) | 36 (285) | 0.45 | 0.86 | 0.57 – 1.3 | 1.2 | 0.73 – 1.9 | |
| Chemo/radiation | 67 (282) | 25 (339) | 0.37 | 0.95 | 0.57 – 1.6 | 0.83 | 0.45 – 1.5 | |
| Surgical resection | 55 (589) | 41 (515) | 0.61 | 0.91 | 0.58 – 1.4 | 0.83 | 0.46 – 1.5 |
*
Log-rank test
**
For serum autoantibody level as a continuous variable